Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure

NCT02142075 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Renal Failure
Critical Care
Gram Positive Bacteria

Interventions

DRUG: Daptomycin

Sponsor

Poitiers University Hospital